Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

Transplanted epithelial stem cells from a healthy eye repaired irreversible corneal injury and restored at least partial ...

Gilead Sciences Inc. closed 0.11% below its 52-week high of $112.11, which the company reached on February 25th.

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $140.00.

Seattle's Nautilus Biotechnology is laying off 16% of workforce, and plans to release its commercial platform in late 2026.

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

Shares have been on the move with the stock up 17.1% over the past month. The stock hit a new 52-week high of $117.39 in the previous session. Gilead Sciences has gained 24.2% since the start of the ...

Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report released on Tuesday, Marketbeat reports. Oppenheimer currently has an ...

Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Stock analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for shares of Gilead Sciences in a research report issued on Tuesday, February 25th. Zacks Research analyst E. Bagri ...